ProCE Banner Activity

postMONARCH: Abemaciclib + Fulvestrant vs Fulvestrant Monotherapy for HR+/HER2- Advanced BC After Progression on CDK4/6 Inhibitor + ET

Conference Coverage
Slideset

Phase III postMONARCH demonstrated significantly improved PFS with abemaciclib plus fulvestrant vs fulvestrant monotherapy after disease progression or recurrence with CDK4/6i plus endocrine therapy in patients with HR+/HER2- advanced breast cancer.

Released: June 03, 2024

Expiration: June 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation